P3-077: EGFR mutations and response to tyrosine kinase inhibitors therapy in NSCLC patients previously treated with chemotherapy  by Crinó, Lucio et al.
Journal of Thoracic Oncology • Volume 2, Number 8, Supplement 4, August 2007  12th World Conference on Lung Cancer
Copyright © 2007 by the International Association for the Study of Lung CancerS710
exon 20 (Y764), and four types of substitution mutation in exon 18 
(E697K), 19 (S754F, D761N), and 21 (L858R). L858R in exon 21 
found in 5 of 10 tumor tissues with mutations was the most frequent 
mutation of EGFR. EGFR mutations were associated with favor-
able response (8 of 10 vs 3 of 20, P = 0.001), signiﬁcantly prolonged 
progression-free survival (PFS; median, 14.0 vs 3.6 month, P = 0.0319) 
and overall survival (OS; median, 17.0 vs 9.2 month, P = 0.0267). 
K-ras Mutations found in 4 patients were the same type: change of G 
to T at the ﬁrst base of codon12 leading to the amino change of glycine 
to cysteine (G12C). K-ras mutations were associated with progressive 
disease, signiﬁcantly decreased PFS (median, 2.5 vs 7.5 month, P = 
0.0108) and OS (median, 5.2 vs 16.3 month, P = 0.007). Only 1 patient 
harbored both EGFR and K-ras mutations. The response rate in EGFR 
mt(+)/K-ras mt(-), EGFR mt(-)/K-ras mt(-), and EGFR mt(-)/K-ras 
mt(+) were 88.9%, 17.6% and 0%, respectively (P<0.001). Interclass 
comparison for response rate: EGFR mt(+)/K-ras mt(-) and EGFR mt(-
)/K-ras mt(-), EGFR mt(+)/K-ras mt(-) and EGFR mt(-)/K-ras mt(+) 
reached statistical signiﬁcance (P =0.001 and P = 0.018, respectively), 
whereas EGFR mt(-)/K-ras mt(-) and EGFR mt(-)/K-ras mt(+) didn’t(P 
= 1.000). The progressive disease rate in EGFR mt(-)/K-ras mt(-) and 
EGFR mt(-)/K-ras mt(+) were 17.6% and 66.7%, P = 0.140. 
Conclusions: For NSCLC patients from China, EGFR mutation is 
a very important biomarker to predict beneﬁt from geﬁtinib, and the 
role of K-ras mutation in predicting response to geﬁtinib needs further 
investigation.
P3-075 NSCLC: Molecular Targeted Therapy Posters, Wed, Sept 5 – Thurs, Sept 6 
A phase II study of erlotinib treatment in advanced non-small 
cell lung cancer after failure of gefitinib: is a clinical benefit still 
achievable? 
Cho, Byoung Chul; Im, Chong-Kun; Kim, Se Kyu; Kim, Joo Hang 
Yonsei Cancer Center, Department of Internal Medicine, Yonsei Univer-
sity College of Medicine, Seoul, Korea
Purpose: This study was designed to evaluate the efﬁcacy and toxic-
ity of erlotinib in patients with advanced non-small cell lung cancer 
(NSCLC) who had progression following treatment with geﬁtinib. 
Methods: The study included stage IIIB/IV recurrent or metastatic 
NSCLC patients who received two or three prior chemotherapy regi-
mens and showed progressive disease within four months of geﬁtinib 
therapy discontinued. Patients received erlotinib 150 mg daily until dis-
ease progression or unacceptable toxicity. EGFR mutations and other 
genetic abnormalities were analyzed from available tumor samples. 
Results: Patient and disease characteristics (n= 21) included median 
age 56 years; number of prior chemotherapy regimens (three, n= 11); 
female (n= 11); adenocarcinoma (n= 15); and never-smoker (n= 11). 
Among the 17 patients with tumor samples available, EGFR mutations 
were detected in 5. The disease control rate (DCR) and response rate 
(RR) for all patients were 28.6% and 9.5%, respectively. The median 
duration of disease control was 125 days. The median time to pro-
gression and overall survival was 60 days and 158 days, respectively. 
Patients who had stable disease (SD) on geﬁtinib showed signiﬁcantly 
higher DCR (75% vs. 17.6% in non-SD patients, P= 0.050) and RR 
(50.0% vs. 0% in non-SD patients, P= 0.029). Among 17 patients with 
biomarker results available, those lacking EGFR mutations who had 
SD on geﬁtinib showed signiﬁcantly higher DCR and RR.
Conclusions: Erlotinib seems to be a potential therapeutic option for 
the treatment of wild-type EGFR, advanced NSCLC patients who had 
SD on geﬁtinib. 
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Background: Single-agent chemotherapy has been considered as 
standard treatment for elderly patients with non-small cell lung cancer 
(NSCLC). However recent subset analyses suggest that platinum-based 
combination chemotherapy may be safely administered to the elderly 
with good performance status (PS). We evaluated the efﬁcacy and 
safety of cisplatin and docetaxel in a phase II study of elderly patients 
aged 70 years or older. 
Methods: Chemotherapy-naive patients aged >70 years with advanced 
NSCLC (IIIB-IV), ECOG performance status (PS) of 0 or 1, a mea-
surable lesion, and adequate organ functions were enrolled. Patients 
received cisplatin (75 mg/m2) and docetaxel (75 mg/m2) administered 
on day 1 every 3 weeks. The primary endpoint was response rate (RR). 
Results: Between October 2004 and September 2006, 26 elderly 
patients with NSCLC were enrolled in the study and all patients were 
treated. Demographics: M/F 17/9; PS 0/1 2/24; median age 75 (range 
70-84). Median number of treatment cycles was 4. Responses in the 26 
evaluable patients included 1CR; 12PR; 7SD; for an objective RR of 
50% (95% CI 31-69%) and a disease control rate of 77%. Median sur-
vival period and 1-year survival rate have not yet been reached. Grade 
3/4 hematologic toxicities included neutropenia (86%), thrombocytope-
nia (5%) and anemia (5%). Non-hematologic toxicities were mild with 
no grade 4 toxicities; grade 3 nausea (9%), anorexia (23%), diarrhea 
(14%), fatigue (9%), allergic reaction (9%) and infection (18%) were 
observed. 
Conclusions: The combination of cisplatin and docetaxel was safe and 
promising for the treatment of chemotherapy-naive elderly patients 
with advanced NSCLC. This regimen warrants further evaluation in a 
phase III trial.
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Background: The aim of this work was to study the association of 
epidermal growth factor receptor (EGFR) mutations and response to 
conventional cytotoxic chemotherapy agents and tyrosine kinase inhibi-
tors (TKIs) in non-small-cell lung cancer patients of Caucasian origin 
since conclusive data have not yet been published. 
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Methods: Patients with stage I to IV NSCLC that were treated with 
geﬁtinib or erlotinib after failure of 1st and 2st-line platinum-based 
chemotherapy were subjected to this analysis. Genomic DNA was 
isolated from parafﬁn-embedded tumor specimens, ampliﬁed for EGFR 
(exons 18, 19, 20 and 21) by touchdown hemi-nested polymerase chain 
reaction and sequenced in both sense and antisense directions. RECIST 
criteria were used to assess response to chemotherapy and TKIs.
Results: This mono-istitutional retrospective analysis was conducted 
on 103 pts from July 2002 to November 2006. Median age was 60 
yrs (range 25-81.5), M/F: 59/44, ECOG-PS 0/1/2/3:68/30/4/1; stage: 
I/II/III/IV 4/5/35/59; adeno/bronchioloalveolar/squamous/large-cells/
other:66/9/20/3/5;never/former/current smokers: 26/20/36. EGFR mu-
tations were detected in 19 pts (18.5%); 13 pts (13.8%) had deletional 
mutations in exon 19, 3 pts (2.9%) had point mutations in exon 20 (one 
patient had two mutations) and 3 pts (2.9%) had missense mutations in 
exon 21. No associations were detected between EGFR mutations and 
adeno/bac histotype (p=0.51), smoke (p=0.23) and gender (p=0.14). 
Disease control rate to TKIs therapy was 54.4%, including 1 complete 
(pt. with EGFR mutations), 21 partial response and 34 stable disease 
and objective response rate was 42%. Median time to progression was 
4.4 months and median survival was 23.7 months. Patients with EGFR 
mutations had a signiﬁcant impact on response rate (PR/CR, 42% 
p=0.015) to TKIs. Instead EGFR mutations did not inﬂuence the re-
sponse to chemotherapy. Cox’s multivariate analysis including gender, 
smoke, stage and histotype showed that EGFR mutations did not reach 
statistical signiﬁcance for progression free survival (PFS) (p=0.52) and 
overall survival (OS) (p=0.50); only adeno/bac histotype was a prog-
nostic factor for longer PFS (p=0.01) and OS (p=0.04).
Conclusions: In our experience EGFR mutations seem to inﬂuence 
response rate in pts treated with TKIs after platinum-based chemother-
apy. These data will be more thoroughly deﬁned by ﬂuorescence in situ 
hybridization analysis of EGFR gene copy number, measurement of 
EGFR and phosphorylated Akt (p-Akt) protein expression by immuno-
histochemistry and KRAS mutations. 
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Background: A randomised phase III trial (Eastern Co-operative 
Oncology Group 4599) has demonstrated that bevacizumab in combi-
nation with standard ﬁrst-line chemotherapy (carboplatin/paclitaxel) 
signiﬁcantly improves outcomes in patients with advanced or recurrent 
non-small cell lung cancer (NSCLC). The MO19390 trial is investigat-
ing the safety proﬁle of bevacizumab in combination with standard 
ﬁrst-line chemotherapy regimens.
Methods: Approximately 2,000 patients from 400 centres world-
wide will be enrolled in this open-label, single-arm trial. The primary 
endpoint is to assess the safety proﬁle of bevacizumab when combined 
with chemotherapy as ﬁrst-line treatment for advanced or recurrent 
NSCLC. Secondary endpoints include time to disease progression and 
overall survival. Eligible patients must have histologically or cytologi-
cally documented locally advanced, metastatic or recurrent non-squa-
mous NSCLC, Eastern Co-operative Oncology Group performance 
status (PS) 0-2 and adequate haematological, liver and renal function. 
Patients with a history of haemoptysis, evidence of tumour invading 
major blood vessels or evidence of CNS metastases are ineligible. 
The selection of the bevacizumab dose for this safety study (15mg/kg 
every 3 weeks) was based on the ECOG 4599 trial. Eligible patients 
will receive bevacizumab in combination with a standard ﬁrst-line 
chemotherapy regimen, which may include non-platinum doublets if 
the centre has speciﬁc experience with an established regimen, and may 
include single-agent chemotherapy for elderly patients or those with PS 
2. Following a maximum of 6 cycles of chemotherapy plus bevaci-
zumab (15mg/kg on day 1 and then every 3 weeks), non-progressing 
patients will continue to receive bevacizumab as maintenance therapy 
until disease progression or unacceptable toxicity. During treatment, 
the incidence of all serious and non-serious bevacizumab-associated 
adverse events will be reported. Additional information about adverse 
events of special interest will be collected (hypertension, proteinuria, 
wound-healing complications, arterial or venous thromboembolic 
events, haemoptysis, CNS bleeding, other haemorrhages, gastrointesti-
nal perforations and congestive heart failure). The planned sample size 
will enable investigation of non-frequent adverse events. All patients 
will be followed up for survival at study end.
Results: Trial enrolment commenced in August 2006. Recruitment is 
expected to continue for approximately 12 months in each participating 
country. As of March 2007, 240 patients have been enrolled (ITT popu-
lation=128) from 17 countries. Median age is 60y (range 28-83). Pa-
tient characteristics (%) are: male/female 64.1/35.9; non-smoker/ex- or 
current-smoker 25.2/74.8 (no data <1); ECOG PS 0/1/2 42.5/53.5/3.9 
(no data <1); adenocarcinoma/other 81/19; stage IIIb/IV 24.4/75.6 (no 
data <1); chemotherapy backbone: cisplatin-gemcitabine/carboplatin-
paclitaxel/carboplatin-gemcitabine/cisplatin-paclitaxel/monotherapy/
non-platinum doublets/other 28.9/25.0/10.9/8.6/3.9/2.3/20.4. To date, 
a total of 61 serious adverse events (SAEs) have been reported, 15 of 
which are considered by the investigator to be study drug related. Six 
of these 15 events have now been resolved. No haemoptysis SAEs have 
been reported to date. 
Conclusions: The large sample size will provide valuable information 
on the safety proﬁle of bevacizumab. Preliminary safety and efﬁcacy 
analyses will be presented at the meeting.
